The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.

På svenska

Author

Summary, in English

We have examined the ability of KW-6002, an adenosine A2a antagonist, to modulate the dyskinetic effects of l-DOPA in 6-hydroxydopamine-lesioned rats. In animals rendered dyskinetic by a previous course of l-DOPA treatment, KW-6002 did not elicit any abnormal involuntary movements on its own, but failed to reduce the severity of dyskinesia when coadministered with l-DOPA. A second experiment was undertaken in order to study the effects of KW-6002 in l-DOPA-naive rats. Thirty-five animals were allotted to four groups to receive a 21-day treatment with: (i) KW-6002 (10 mg/kg/day); (ii) l-DOPA (6 mg/kg/day) i.p.; (iii) KW-6002 plus l-DOPA (same doses as above) or (iv) vehicle. Chronic treatment with KW-6002-only produced a significant relief of motor disability in the rotarod test in the absence of any abnormal involuntary movements. Combined treatment with l-DOPA and KW-6002 improved rotarod performance to a significantly higher degree than did each of the two drugs alone. However, this combined treatment induced dyskinesia to about the same degree as did l-DOPA alone. In situ hybridization histochemistry showed that KW-6002 treatment alone caused an approximately 20% reduction in the striatal levels of preproenkephalin mRNA, whereas neither the coadministration of KW-6002 and l-DOPA nor l-DOPA alone significantly altered the expression of this transcript in the dopamine-denervated striatum. Either alone or in combination with l-DOPA, KW-6002 did not have any modulatory effect on prodynorphin mRNA expression or FosB/ΔFosB-like immunoreactivity in the dopamine-denervated striatum.



These results show that monotreatment with an adenosine A2a receptor antagonist can relieve motor disability without inducing behavioural and cellular signs of dyskinesia in rats with 6-hydroxydopamine lesions. Cotreatment with KW-6002 and l-DOPA potentiates the therapeutic effect but not the dyskinesiogenic potential of the latter drug.

Publishing year

2003

Language

English

Pages

1398-1410

Publication/Series

Journal of Neurochemistry

Volume

84

Issue

6

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Neurosciences

Keywords

  • Parkinsonian Disorders: chemically induced
  • Oxidopamine
  • Levodopa: adverse effects
  • Motor Activity: drug effects
  • Female
  • Enkephalins: metabolism
  • Enkephalins: genetics
  • Disease Models
  • Animal
  • Behavior
  • Drug Therapy
  • Combination
  • Dyskinesia
  • Drug-Induced: complications
  • Drug-Induced: drug therapy
  • Corpus Striatum: metabolism
  • Corpus Striatum: drug effects
  • Animal: drug effects
  • Parkinsonian Disorders: complications
  • Parkinsonian Disorders: drug therapy
  • Protein Precursors: genetics
  • Protein Precursors: metabolism
  • Proto-Oncogene Proteins c-fos: metabolism
  • Purines: pharmacology
  • RNA
  • Messenger: metabolism
  • Rats
  • Sprague-Dawley
  • Receptors
  • Purinergic P1: antagonists & inhibitors
  • Treatment Outcome

Status

Published

Research group

  • Neurobiology
  • Neuronano Research Center (NRC)
  • Basal Ganglia Pathophysiology

ISBN/ISSN/Other

  • ISSN: 1471-4159